Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lomerizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.95 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.95 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.95 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.95 |
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.64 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.95 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.95 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.95 |
| ▸ | DRD2 | P14416 | 1/20 | 0.95 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.95 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.95 |
| ▸ | CNR1 | P21554 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | HRH1 | P35367 | 1/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.95 |
| ▸ | DRD3 | P35462 | 1/20 | 0.95 |
| ▸ | HTR2B | P41595 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomerizine SCHEMBL29496366 | 0.98 | LMNA (1.00) | LMNACHRM2OPRK1ADORA3CHRM1 | |
| Lomerizine SCHEMBL79390 | 0.98 | LMNA (1.00) | LMNACHRM2OPRK1ADORA3CHRM1 | |
| Lomerizine SCHEMBL29439945 | 0.96 | LMNA (0.98) | LMNACHRM2OPRK1ADORA3CHRM1 | |
| Lomerizine SCHEMBL404179 | 0.96 | LMNA (0.98) | LMNACHRM2OPRK1ADORA3CHRM1 | |
| Lomerizine SCHEMBL1153647 | 0.96 | LMNA (0.98) | LMNACHRM2OPRK1ADORA3CHRM1 | |
| SCHEMBL1152274 | 0.93 | LMNA (0.91) | LMNACHRM2OPRK1ADORA3CHRM1 | |
| Hydrochloric Acid SCHEMBL7324923 | 0.92 | LMNA (0.89) | LMNACHRM2OPRK1ADORA3CHRM1 | |
| Lomerizine SCHEMBL10731133 | 0.88 | LMNA (0.82) | LMNACHRM2OPRK1ADORA3CHRM1 | |
| Lomerizine SCHEMBL10731150 | 0.88 | LMNA (0.82) | LMNACHRM2OPRK1ADORA3CHRM1 | |
| SCHEMBL6138969 | 0.87 | LMNA (0.81) | LMNACHRM2OPRK1ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20250003952-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | KYOTO UNIVERSITY (JP) | 2025-01-02 | — | — | US | disclosed |
| EP-4400117-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | Kyoto University (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024135719-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | 国立大学法人京都大学 | 2024-06-27 | — | — | WO | disclosed |
| CN-117915953-A | Method for screening senescent cell scavenger and senescent cell scavenger | 国立大学法人京都大学 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023038027-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | 国立大学法人京都大学 | 2023-03-16 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | AMPLA PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | ADRB3, FFAR3, SLC6A4 | CHRM2 209/4885CHRM1 211/4885SLC6A2 5/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | CHRM2 880/4885CHRM1 1604/4885SLC6A2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.